In vivo and in vitro characterization of naltrindole-derived ligands at the κ-opioid receptor

Journal of Psychopharmacology

Volumn 27, Issue 2, 2013, Pages 192-202

  Casal Dominguez, Joseph J ^a   Clark, Mary ^b   Traynor, John R ^b   Husbands, Stephen M ^a   Bailey, Sarah J ^a  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

anxiety; Depression; kappa antagonist; kappa opioid receptor; mu antagonist; norBNI

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; 5' (2 AMINOMETHYL)NALTRINDOLE; KAPPA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR ANTAGONIST; MU OPIATE RECEPTOR ANTAGONIST; N [(NALTRINDOL 5 YL)METHYL]PENTANIMIDAMIDE; NALTRINDOLE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ANTINOCICEPTION; ANXIETY; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DEPRESSION; DIURESIS; DRUG SELECTIVITY; GUINEA PIG; ILEUM; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RECEPTOR BINDING; TRANQUILIZING ACTIVITY;

ANALGESICS; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; DEPRESSION; GUINEA PIGS; LIGANDS; MALE; MICE; NALTREXONE; NARCOTIC ANTAGONISTS; RATS; RATS, WISTAR; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU;

EID: 84872839981     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112464828     Document Type: Article

References (66)

1. Belcheva MM, Vogel Z, Ignatova E, et al. Opioid modulation of extracellular signal-regulated protein kinase activity is ras-dependent and involves Gbetagamma subunits. J Neurochem. 1998 ; 70: 635-645
2. Berrocoso E, Sanchez-Blazquez P, Garzon J, et al. Opiates as antidepressants. Curr Pharm Des. 2009 ; 15: 1612-1622
3. Birch PJ, Hayes AG, Sheehan MJ, et al. Norbinaltorphimine: antagonist profile at kappa opioid receptors. Eur J Pharmacol. 1987 ; 144: 405-408
4. Blaschko H. Amine oxidase and amine metabolism. Pharmacol Rev. 1952 ; 4: 415-458
5. Bruchas MR, Chavkin C. Kinase cascades and ligand-directed signaling at the kappa opioid receptor. Psychopharmacology (Berl). 2010 ; 210: 137-147
6. Bruchas MR, Land BB, Aita M, et al. Stress-induced p38 mitogen-activated protein kinase activation mediates kappa-opioid-dependent dysphoria. J Neurosci. 2007 ; 27: 11614-11623
7. Bruchas MR, Land BB, Chavkin C. The dynorphin/kappa opioid system as a modulator of stress-induced and pro-addictive behaviors. Brain Res. 2010 ; 1314: 44-55
8. Burke TF, Woods JH, Lewis JW, et al. Irreversible opioid antagonist effects of clocinnamox on opioid analgesia and mu receptor binding in mice. J Pharmacol Exp Ther. 1994 ; 271: 715-721
9. Cami-Kobeci G, Neal AP, Bradbury FA, et al. Mixed kappa/mu opioid receptor agonists: the 6 beta-naltrexamines. J Med Chem. 2009 ; 52: 1546-1552
10. Carlezon WA, Beguin C, DiNieri JA, et al. Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats. J Pharmacol Exp Ther. 2006 ; 316: 440-447
11. Clark MJ, Emmerson PJ, Mansour A, et al. Opioid efficacy in a C6 glioma cell line stably expressing the delta opioid receptor. J Pharmacol Exp Ther. 1997 ; 283: 501-510
12. Crawley JN. Exploratory behavior models of anxiety in mice. Neuroscience Biobehav Rev. 1985 ; 9: 37-44
13. Cryan JF, Mombereau C, Vassout A. The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev. 2005a ; 29: 571-625
14. Cryan JF, Page ME, Lucki I. Differential behavioral effects of the antidepressants reboxetine, fluoxetine, and moclobemide in a modified forced swim test following chronic treatment. Psychopharmacology (Berl). 2005b ; 182: 335-344
15. DePaoli AM, Hurley KM, Yasada K, et al. Distribution of κ opioid receptor mRNA in adult mouse brain: an in situ hybridization histochemistry study. Mol Cell Neurosci. 1994 ; 5: 327-335
16. Emmerson PJ, Clark MJ, Mansour A, et al. Characterization of opioid agonist efficacy in a C6 glioma cell line expressing the mu opioid receptor. J Pharmacol Exp Ther. 1996 ; 278: 1121-1127
17. Emrich HM, Gunther R, Dose M. Current perspectives in the pharmacopsychiatry of depression and mania. Neuropharmacology. 1983 ; 22: 385-388
18. Emrich HM, Vogt P, Herz A. Possible antidepressive effects of opioids: Action of buprenorphine. Ann N Y Acad Sci. 1982 ; 398: 108-112
19. Endoh T, Matsuura H, Tanaka C, et al. Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther. 1992 ; 316: 30-42
20. Fukui M, Rodriguiz RM, Zhou J, et al. Vmat2 heterozygous mutant mice display a depressive-like phenotype. J Neurosci. 2007 ; 27: 10520-10529
21. Hampson RE, Mu J, Deadwyler SA. Cannabinoid and kappa opioid receptors reduce potassium K current via activation of G(s) proteins in cultured hippocampal neurons. J Neurophysiol. 2000 ; 84: 2356-2364
22. Horan P, Taylor J, Yamamura HI, et al. Extremely long-lasting antagonistic actions of nor-binaltorphimine (nor-BNI) in the mouse tail-flick test. J Pharmacol Exp Ther. 1992 ; 260: 1237-1243
23. Ide S, Fujiwara S, Fujiwara M, et al. Antidepressant-like effect of venlafaxine is abolished in mu-opioid receptor-knockout mice. J Pharmacol Sci. 2010 ; 114: 107-110
24. Irwin S. Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse. Psychopharmacologia. 1968 ; 13: 222-257
25. Jacobson L, Cryan J. Feeling strained? Influence of genetic background on depression-related behavior in mice: a review. Behav Genet. 2007 ; 37: 171-213
26. Jales AR, Husbands SM, Lewis JW. Selective κ-opioid antagonists related to naltrindole. effect of side-chain spacer in the 5′-amidinoalkyl series. Bioorg Med Chem Lett. 2000 ; 10: 2259-2261
27. Jones DN, Holtzman SG. Long term kappa-opioid receptor blockade following nor-binaltorphimine. Eur J Pharmacol. 1992 ; 215: 345-348
28. Kenakin TP A Pharmacology Primer: Theory, Applications and Methods. 2009 ) A Pharmacology Primer: Theory, Applications and Methods. 3rd edn. San Diego, USA: Elsevier Academic Press. San Diego, USA: Elsevier Academic Press ; 2009 :
29. Kitchen I, Slowe SJ, Matthes HWD, et al. Quantitative autoradiographic mapping of μ-, δ- and κ-opioid receptors in knockout mice lacking the μ-opioid receptor gene. Brain Res. 1997 ; 778: 73-88
30. Knoll AT, Carlezon WA. Dynorphin, stress, and depression. Brain Res. 2010 ; 1314: 56-73
31. Lee KO, Akil H, Woods JH, et al. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors. Eur J Pharmacol. 1999 ; 378: 323-330
32. Lewis SR, Ahmed S, Dym C, et al. Inbred mouse strain survey of sucrose intake. Physiol Behav. 2005 ; 85: 546-556
33. Lin S, Boey D, Lee N, et al. Distribution of prodynorphin mRNA and its interaction with the NPY system in the mouse brain. Neuropeptides. 2006 ; 40: 115-123
34. Lister RG. The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl). 1987 ; 92: 180-185
35. Lucki I, Dalvi A, Mayorga AJ. Sensitivity to the effects of pharmacologically selective antidepressants in different strains of mice. Psychopharmacology (Berl). 2001 ; 155: 315-22
36. Lynch WC, Burns G. Opioid effects on intake of sweet solutions depend both on prior drug experience and on prior ingestive experience. Appetite. 1990 ; 15: 23-32
37. McLaughlin JP, Land BB, Li S, et al. Prior activation of kappa opioid receptors by U50,488 mimics repeated forced swim stress to potentiate cocaine place preference conditioning. Neuropsychopharmacology. 2006a ; 31: 787-794
38. McLaughlin JP, Li S, Valdez J, et al. Social defeat stress-induced behavioral responses are mediated by the endogenous kappa opioid system. Neuropsychopharmacology. 2006b ; 31: 1241-1248
39. McLaughlin JP, Marton-Popovici M, Chavkin C. Kappa opioid receptor antagonism and prodynorphin gene disruption block stress-induced behavioral responses. J Neurosci. 2003 ; 23: 5674-5683
40. Mague SD, Pliakas AM, Todtenkopf MS, et al. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats. J Pharmacol Exp Ther. 2003 ; 305: 323-330
41. Mansour A, Fox CA, Meng F, et al. [Kappa] 1 Receptor mRNA distribution in the rat CNS: Comparison to [kappa] receptor binding and prodynorphin mRNA. Mol Cell Neurosci. 1994 ; 5: 124-144
42. Melief EJ, Miyatake M, Bruchas MR, et al. Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A. 2010 ; 107: 11608-11613
43. Melief EJ, Miyatake M, Carroll FI, et al. Duration of action of a broad range of selective kappa-opioid receptor antagonists is positively correlated with c-Jun N-terminal kinase-1 activation. Mol Pharmacol. 2011 ; 80: 920-929
44. Mizoguchi H, Wu HE, Narita M, et al. Antagonistic property of buprenorphine for putative epsilon-opioid receptor-mediated G-protein activation by beta-endorphin in pons/medulla of the mu-opioid receptor knockout mouse. Neuroscience. 2002 ; 115: 715-721
45. Muscat R, Papp M, Willner P. Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology (Berl). 1992 ; 109: 433-438
46. Newton SS, Thome J, Wallace TL, et al. Inhibition of cAMP response element-binding protein or dynorphin in the nucleus accumbens produces an antidepressant-like effect. J Neurosci. 2002 ; 22: 10883-10890
47. O'Reilly KC, Shumake J, Gonzalez-Lima F, et al. Chronic administration of 13-cis-retinoic acid increases depression-related behavior in mice. Neuropsychopharmacology. 2006 ; 31: 1919-1927
48. Olmsted SL, Takemori AE, Portoghese PS. A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetic kappa address element to the delta antagonist, naltrindole: 5'-[M"-alkylamidino) methyl]naltrindole derivatives as a novel class of kappa opioid receptor antagonists. J Med Chem. 1993 ; 36: 179-180
49. Peters MF, Zacco A, Gordon J, et al. Identification of short- acting κ-opioid receptor antagonists with anxiolytic-like activity. Eur J Pharmacol. 2011 ; 661: 27-34
50. Pfeiffer A, Brantl V, Herz A, et al. Psychotomimesis mediated by kappa opiate receptors. Science. 1986 ; 233: 774-776
51. Rothman RB, Gorelick DA, Heishman SJ, et al. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. J Subst Abuse Treat. 2000 ; 18: 277-281
52. Ruegg H, Yu WZ, Bodnar RJ. Opioid-receptor subtype agonist-induced enhancements of sucrose intake are dependent upon sucrose concentration. Physiol Behav. 1997 ; 62: 121-128
53. Sabelli HC, Javaid JI. Phenylethylamine modulation of affect: therapeutic and diagnostic implications. J Neuropsychiatry Clin Neurosci. 1995 ; 7: 6-14
54. Schwarzer C. 30 years of dynorphins - new insights on their functions in neuropsychiatric diseases. Pharmacol Ther. 2009 ; 123: 353-370
55. Shirayama Y, Ishida H, Iwata M, et al. Stress increases dynorphin immunoreactivity in limbic brain regions and dynorphin antagonism produces antidepressant-like effects. J Neurochem. 2004 ; 90: 1258-1268
56. Simen AA, Miller RJ. Structural features determining differential receptor regulation of neuronal Ca channels. J Neurosci. 1998 ; 18: 3689-3698
57. Steru L, Chermat R, Thierry B, et al. The tail suspension test: a new method for screening antidepressants in mice. Psychopharmacology (Berl). 1985 ; 85: 367-370
58. Stevens WC, Jones RM, Subramanian G, et al. Potent and selective indolomorphinan antagonists of the kappa-opioid receptor. J Med Chem. 2000 ; 43: 2759-2769
59. Tejeda HA, Shippenberg TS, Henriksson R. The dynorphin/κ-opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci. 2012 ; 69: 857-896
60. Todtenkopf MS, Marcus JF, Portoghese PS, et al. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology (Berl). 2004 ; 172: 463-470
61. Traynor JR, Nahorski SR. Modulation by mu-opioid agonists of guanosine-5'-O-(3-[35S]thio)triphosphate binding to membranes from human neuroblastoma SH-SY5Y cells. Mol Pharmacol. 1995 ; 47: 848-854
62. Van der Heyden JA, Molewijk E, Olivier B. Strain differences in response to drugs in the tail suspension test for antidepressant activity. Psychopharmacology (Berl). 1987 ; 92: 127-130
63. Wang D, Sun X, Sadee W. Different effects of opioid antagonists on mu-, delta-, and kappa-opioid receptors with and without agonist pretreatment. J Pharmacol Exp Ther. 2007 ; 321: 544-552
64. Wiley MD, Poveromo LB, Antapasis J, et al. Kappa-opioid system regulates the long-lasting behavioral adaptations induced by early-life exposure to methylphenidate. Neuropsychopharmacology. 2009 ; 34: 1339-1350
65. Wittmann W, Schunk E, Rosskothen I, et al. Prodynorphin-derived peptides are critical modulators of anxiety and regulate neurochemistry and corticosterone. Neuropsychopharmacology. 2009 ; 34: 775-785
66. Zhang H, Shi YG, Woods JH, et al. Central kappa-opioid receptor-mediated antidepressant-like effects of nor-Binaltorphimine: behavioral and BDNF mRNA expression studies. Eur J Pharmacol. 2007 ; 570: 89-96